Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses
Viruses · 21.05.2026 · 18 (5) · 582
DOI: 10.3390/v18050582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 21.05.2026. Verfasst von Shuai Shang und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China. Hauptthemen laut MEDLINE: Encephalitis Virus, Japanese, Japanese Encephalitis Vaccines, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing City Natural Science Foundation Project.
Abstract (Originalsprache)
Japanese encephalitis virus (JEV) comprises a single serotype but can be classified into five genotypes (genotypes I–V, GI–GV) based on nucleic acid sequences. Historically, genotype III (GIII) was the predominant strain. However, since the 21st century, genotype I (GI) rapidly replaced GIII as the major genotype in China, Southeast Asia, and other regions. The live attenuated vaccine (LAV) SA14-14-2, licensed in China in 1988, was successfully exported to 13 countries, with cumulative vaccinations exceeding one billion doses. The vaccine seed virus SA14-14-2 belonged to genotype III. Whether this GIII-based vaccine provided sufficient protection against the currently circulating GI strains warranted systematic investigation. In this study, recent JEV isolates collected from China were subjected to genotypic analysis, followed by comprehensive evaluations including protective efficacy against challenge and serum neutralizing antibody levels. The results indicated that, despite antigenic differences between GIII and GI strains, no significant differences in protective efficacy post-challenge were observed. The SA14-14-2 LAV remained effective in preventing GI strain infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
- Changchun Institute of Biological Products Co., Ltd., Changchun 130015, China.
- State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Beijing 100024, China.
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, Ch…
ORCID-Profile: Qikai Yin, Huanyu Wang
Förderung
- Beijing City Natural Science Foundation Project
Zitieren
APA
Shang, S., Yin, Q., Che, T., Wang, X., Su, Q., Fu, S., Xu, H., Yu, Y., Mao, Q., Wang, H., & Liu, X. (2026). Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses. Viruses, 18(5), 582. https://doi.org/10.3390/v18050582
Vancouver
Shang S, Yin Q, Che T, Wang X, Su Q, Fu S, et al. Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses. Viruses. 2026;18(5):582. doi:10.3390/v18050582
BibTeX
@article{Shang2026,
author = {Shang, Shuai and Yin, Qikai and Che, Tingyi and Wang, Xinzhu and Su, Qi and Fu, Shihong and Xu, Hongshan and Yu, Yongxin and Mao, Qunying and Wang, Huanyu and Liu, Xinyu},
title = {Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses},
journal = {Viruses},
year = {2026},
volume = {18},
number = {5},
pages = {582},
doi = {10.3390/v18050582}
}
EUVIMED